Joana Carvalho, PhD, managing science editor —

Fatigue can be a significant burden for people with idiopathic pulmonary fibrosis (IPF), and tends to worsen as the disease progresses or, at best, stay “relatively” stable, a study found. Increasing fatigue was particularly evident among younger patients who were least affected at the study’s start, and among those…

Endeavor BioMedicines has raised $62 million in series A funding to support the launch of two Phase 2 trials evaluating taladegib (ENV-101), its investigational candidate for the treatment of idiopathic pulmonary fibrosis (IPF), the company announced in a press release. The therapy is designed to target the underlying…

iBio has received a U.S. patent for its method of increasing the amount and quality of endostatin-derived peptides generated from the company’s plant-based FastPharming protein production system. These peptides, which have been shown to possess strong anti-fibrotic or anti-scarring properties, make up part of IBIO-100, an experimental…

GLPG1205, an investigational therapy by Galapagos, was found to be safe and well tolerated, with an ability to lower lung function decline in adults with idiopathic pulmonary fibrosis (IPF), according to results from a Phase 2 clinical trial. Top-line data from the study, called PINTA (…

A first patient has been enrolled in a proof-of-concept Phase 2 trial of C21 (VP01), Vicore Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other lung diseases. “We are pleased to announce that we can now start our IPF trial despite the ongoing COVID-19…

People with idiopathic pulmonary fibrosis (IPF) who have three or more abnormally large lymph nodes in the area of the lungs and heart — a condition known as mediastinal lymph node enlargement (LNE) — have an increased risk of mortality and faster disease progression, a study found. The…

Patients diagnosed with idiopathic pulmonary fibrosis (IPF) in more recent years appear to have a lower risk of mortality on a short-term basis than those diagnosed more than 10 years ago, a study has found. According to the researchers, these differences in short-term mortality may be due to changes…

The Centers for Medicare and Medicaid Services (CMS) has given the status of Advanced Diagnostic Laboratory Test (ADLT) to the Envisia Genomic Classifier, Veracyte’s genomic test specifically designed to facilitate the diagnosis of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The…

NXP004, Nuformix’s potential anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF), led to a dose-dependent reduction in the production and deposition of proteins that are known key drivers of fibrosis (tissue scarring) and IPF progression, a preclinical study shows. Although these are preliminary findings in a tissue study,…

Ofev (nintedanib) helped more patients with progressive fibrosing interstitial lung diseases (ILDs) avoid a decline in lung function greater than 10% over the course of a year compared with those given a placebo, according to a new analysis of the Phase 3 INBUILD trial. A separate analysis…